Our clinical drug candidate HOPO-101 is designed to selectively bind to a range of heavy metals and promote their rapid clearance and excretion from the body. Unlike most other chelating agents, HOPO-101 leaves essential minerals and metal ions undisturbed in the body. This unique selectivity avoids one of the most problematic toxicity mechanisms of many other chelating agents, enabling a chronic dosing approach not possible with existing treatments.
In nonclinical studies, HOPO-101 has consistently demonstrated its effectiveness in chelating and removing a wide array of heavy metals. These include common environmental toxins like lead, cadmium, and tin, as well as most lanthanides and the radioactive actinide elements.
Most existing chelating agents are administered intravenously by a healthcare professional, which is poorly suited for low-resource care settings like a disaster scenario or rural or underserved populations. HOPO-101 is being developed in oral dosage forms to enable rapid, widespread deployment, as well as convenient self-administration outside of a hospital or other treatment setting.
The innovative design of HOPO-101 enables it to target a broad range of heavy metals while largely avoiding essential physiological metal ions like calcium, magnesium, zinc, and copper. This selectivity is crucial for both the excellent safety and broad efficacy profiles observed in nonclinical studies.
Nonclinical studies have shown that HOPO-101 can be highly effective at both removing heavy metals from the body after exposure, as well as preventing the deposition of heavy metals if used in a prophylactic manner. This enables treatment for both patients who have been exposed, as well as first responders or other personnel entering a contaminated area.
HOPO-101 and all related products described on this site are STRICTLY INVESTIGATIONAL and have not been definitely shown to be safe OR effective in clinical trials. The statements made herein are based solely on studies carried out in animals and reflect the best good faith scientific assessment of the company and its management and scientific personnel. None of these statements have been evaluated by the FDA, and HOPO-101 is not FDA-approved for any use or indication. Additional studies are necessary before any definitive conclusions can made.